About: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Background/Aims Previous studies using standard interferon and ribavirin combination therapy suggested that patients infected with HCV-1 and a low pretreatment HCV-RNA level can be treated for 24 weeks without compromising sustained virologic response rates. The aim of the present study was to investigate this schedule in the era of pegylated interferon- plus ribavirin. Methods Patients chronically infected with HCV-1 (n=235) and a screening viremia ≤600,000 IU/mL (real-time PCR) were treated with peginterferon alfa-2b 1.5 μg/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day based on body weight for 24 weeks. Results End-of-treatment and sustained virologic response rates were 80 and 50%, respectively. The 48-week historical control (Manns et al., Lancet 2001;358:958-65) had similar end-of-treatment (74%) but higher sustained virologic response rates (71%). This difference was due to a high virologic relapse rate after 24 weeks of therapy (37%) compared with the
  • Background/Aims Previous studies using standard interferon and ribavirin combination therapy suggested that patients infected with HCV-1 and a low pretreatment HCV-RNA level can be treated for 24 weeks without compromising sustained virologic response rates. The aim of the present study was to investigate this schedule in the era of pegylated interferon- plus ribavirin. Methods Patients chronically infected with HCV-1 (n=235) and a screening viremia ≤600,000 IU/mL (real-time PCR) were treated with peginterferon alfa-2b 1.5 μg/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day based on body weight for 24 weeks. Results End-of-treatment and sustained virologic response rates were 80 and 50%, respectively. The 48-week historical control (Manns et al., Lancet 2001;358:958-65) had similar end-of-treatment (74%) but higher sustained virologic response rates (71%). This difference was due to a high virologic relapse rate after 24 weeks of therapy (37%) compared with the (en)
  • interferon, ribavirin, HCV-1, mírná virémie před léčbou, RNA (cs)
Title
  • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
  • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia (en)
  • Účinnost 24týdenní léčby peginterferonem alfa-2b plus ribavirinem u pacientů s chronickou hepatitidou typu C infikovaných genotypem 1 a s mírnou virémií před léčbou (cs)
skos:prefLabel
  • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
  • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia (en)
  • Účinnost 24týdenní léčby peginterferonem alfa-2b plus ribavirinem u pacientů s chronickou hepatitidou typu C infikovaných genotypem 1 a s mírnou virémií před léčbou (cs)
skos:notation
  • RIV/00023001:_____/06:00001408!RIV08-MZ0-00023001
http://linked.open.../vavai/riv/strany
  • 97-103
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • N
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 473406
http://linked.open...ai/riv/idVysledku
  • RIV/00023001:_____/06:00001408
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • hepatology (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [200F1961010A]
http://linked.open...i/riv/nazevZdroje
  • Journal of Hepatology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 44
http://linked.open...iv/tvurceVysledku
  • Buti, M.
  • Zeuzem, S.
  • Šperl, Jan
  • Albrecht, J.
  • Brass, C.
  • Cianciara, J.
  • Ferenci, P.
  • Horsmans, Y.
  • Ibranyi, E.
  • Noviello, S.
  • Weiland, O.
issn
  • 0168-8278
number of pages
is http://linked.open...avai/riv/vysledek of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 30 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software